What is Quetiapine?
Quetiapine (brand name Seroquel) is a second-generation (atypical) antipsychotic medication that blocks multiple neurotransmitter receptors including dopamine, serotonin, histamine, and adrenergic receptors. 1, 2
FDA-Approved Indications
Quetiapine is FDA-approved for:
- Schizophrenia (ages 13 and older) 3, 1, 4
- Acute manic episodes in bipolar disorder (ages 10 and older) 3, 1
- Bipolar depression in adults 3, 4
- Maintenance treatment of bipolar disorder in adults 3
Mechanism of Action
The drug exhibits antagonistic effects on multiple receptor systems 2:
- Serotonin receptors (5-HT1A and 5-HT2A) 2
- Dopamine receptors (D1 and D2) with binding characteristics similar to clozapine 2
- Histamine H1 receptors (responsible for sedating effects) 2
- Adrenergic alpha1 and alpha2 receptors 2
This multi-receptor profile produces antipsychotic effects with reduced risk of extrapyramidal symptoms compared to typical antipsychotics 5, 2.
Available Formulations
Quetiapine tablets are available in multiple strengths 1:
- 25 mg (round, pink tablets) 1
- 50 mg (round, white to off-white tablets) 1
- 100 mg (round, yellow tablets) 1
- 200 mg (round, white to off-white tablets) 1
- 300 mg (capsule-shaped, white tablets) 1
- 400 mg (capsule-shaped, yellow tablets) 1
Pharmacokinetics
Key pharmacokinetic properties include 2:
- Linear pharmacokinetics across the therapeutic dose range 2
- Mean terminal half-life of 7 hours 2
- Hepatic metabolism as the primary route of elimination 2
- Not affected by smoking 2
- Dose adjustment required in elderly patients and those with hepatic impairment 2
Common Off-Label Uses
Despite lacking FDA approval for these indications, quetiapine is frequently prescribed off-label for 6, 7, 8:
- Insomnia (typically at low doses of 25-200 mg) due to its sedating properties 6, 7, 9
- Anxiety disorders, particularly generalized anxiety disorder when sedation is desired 6, 9
- Behavioral disturbances in dementia (though this carries significant safety concerns) 5, 10
Dosing Guidelines
For Approved Psychiatric Indications
- Optimal dosing range: 150-750 mg/day for schizophrenia and bipolar disorder 2
- Initiation: Start low and titrate gradually 5
- Once-daily dosing may be suitable for some patients 2
For Off-Label Sedation/Anxiety
According to recent evidence-based guidelines 6:
- Starting dose: 25 mg at bedtime 6
- Titration: Increase to 50 mg after 2-3 days if tolerated 6
- Effective range: 25-200 mg per day 6
- Higher doses can be divided into twice-daily administration 6
Critical Safety Warnings
Black Box Warning
The FDA mandates a black box warning regarding increased risk of death when used for behavioral control in dementia-related psychosis 10.
Major Adverse Effects
Metabolic complications 11, 1:
- Weight gain (can be extreme) 12, 1
- Hyperglycemia and diabetes risk 1
- Dyslipidemia (elevated cholesterol and triglycerides) 1
- Orthostatic hypotension (especially during dose titration) 5, 6, 1
- QT prolongation (particularly concerning in youth) 13, 12
- Increased blood pressure in children and adolescents 1
- Extrapyramidal symptoms (lower risk than typical antipsychotics but still possible) 5, 12
- Sedation and somnolence (predictable and dose-related) 6, 1
- Cognitive impairment in elderly patients 10
Specific Populations at Higher Risk
Elderly patients face increased risks of 10, 7:
- Mortality (3.1-fold increased risk compared to trazodone) 7
- Dementia (7.1-8.1-fold increased risk) 7
- Falls and fractures (2.8-fold increased risk) 7
- Cognitive decline 10
Patients with Parkinson's disease or Lewy body dementia should avoid quetiapine as first-line therapy due to heightened extrapyramidal risk 6.
Required Monitoring
Before initiating treatment, obtain 11:
- BMI and waist circumference 11
- Blood pressure 11
- Fasting glucose or HbA1c 11
- Lipid profile 11
- Prolactin level 11
- Liver function tests 11
- Complete blood count 11
- Electrocardiogram 11
- Weekly weight and blood pressure for first 6 weeks 11
- Fasting glucose at 4 weeks after initiation 11
- Comprehensive metabolic panel at 3 months, then annually 11
- CBC monitoring in patients with pre-existing low WBC 1
- Eye examinations at baseline and 6 months (FDA recommendation, though cataract risk not confirmed in humans) 12
Drug Interactions
CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) significantly increase quetiapine exposure; reduce quetiapine dose to one-sixth when co-administered 1.
CYP3A4 inducers (phenytoin, carbamazepine, rifampin) dramatically decrease quetiapine levels; may require up to 5-fold dose increase to maintain efficacy 1.
Alcohol and CNS depressants potentiate cognitive and motor impairment; limit alcohol consumption during treatment 1.
Antihypertensive agents: quetiapine may enhance hypotensive effects 1.
Abuse Potential
Despite being an antipsychotic, case reports document quetiapine abuse, particularly among 4:
- Prisoners 4
- Patients with substance use disorders 4
- Routes of abuse include intranasal and intravenous administration 4
- Abuse is attributed to anxiolytic and sedative effects 4
Clinical Decision-Making for Off-Label Use
When considering quetiapine for insomnia or anxiety 6:
- Reserve for cases where first-line treatments (SSRIs, SNRIs) have failed or are contraindicated 6
- Appropriate when comorbid insomnia with severe agitation is present 6
- Never use as first-line monotherapy for uncomplicated anxiety 6
- Avoid combining with benzodiazepines due to risk of respiratory depression and fatalities 6
- Use lowest effective dose for shortest duration necessary 6
- Consider alternatives like trazodone or mirtazapine, which have superior safety profiles in elderly patients 7
Comparative Positioning Among Atypicals
- Higher anticholinergic burden than aripiprazole or risperidone 11
- More sedating than most other atypicals 5
- Lower risk of extrapyramidal symptoms than risperidone 5
- Comparable metabolic risk to olanzapine and clozapine 11
- No demonstrated efficacy for relapse prevention in cannabis-induced psychosis (unlike other atypicals) 14